ABBV Mar 2025 130.000 put
| Previous close | 0.7000 |
| Open | 1.0900 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 130.00 |
| Expiry date | 2025-03-21 |
| Day's range | 0.7000 - 1.0900 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
PR NewswireAvailable Nationwide: JUVÉDERM® VOLUMA® XC for Moderate to Severe Temple Hollowing
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the national availability of JUVÉDERM® VOLUMA® XC for temple hollowing. Following its U.S. FDA approval in March 2024, JUVÉDERM® VOLUMA® XC is the first and only hyaluronic acid (HA) filler approved to treat moderate to severe temple hollowing in adults over 21.1,2 The JUVÉDERM® Collection of Fillers is the number one chosen HA dermal filler brand by patients and providers, and now offers the largest range of treatment indications to
ZacksShould You Buy AbbVie Stock After Recent Parkinson's Study Success?
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.
PR NewswireAbbVie to Host Third-Quarter 2024 Earnings Conference Call
AbbVie (NYSE: ABBV) will announce its third-quarter 2024 financial results on Wednesday, October 30, 2024, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.
